Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23080486 | 0.92 | AR (0.66) | ARABCG2PGR | |
| SCHEMBL20003364 | 0.90 | AR (0.64) | ARABCG2PGR | |
| SCHEMBL20003361 | 0.90 | AR (0.77) | ARABCG2HDAC1PGR | |
| SCHEMBL21155659 | 0.90 | AR (0.64) | ARABCG2PGR | |
| SCHEMBL20003367 | 0.89 | AR (0.63) | ARABCG2PGR | |
| SCHEMBL21155289 | 0.88 | AR (0.61) | ARABCG2HDAC1PGR | |
| SCHEMBL1715463 | 0.87 | AR (0.82) | ARABCG2HDAC1PGR | |
| SCHEMBL17941171 | 0.85 | AR (0.78) | ARABCG2HDAC1PGR | |
| SCHEMBL20003393 | 0.84 | AR (0.64) | ARABCG2HDAC1PGR | |
| SCHEMBL20003478 | 0.84 | AR (0.57) | ARABCG2HDAC1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | AR 2/4885ABCG2 3832/4885HDAC1 183/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885ABCG2 3832/4885HDAC1 183/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885ABCG2 3583/4885HDAC1 2205/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885ABCG2 3832/4885HDAC1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.